ProQR Therapeutics Files Routine 6-K Report on March 25, 2026
Ticker: PRQR · Form: 6-K · Filed: Mar 25, 2026 · CIK: 0001612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | Mar 25, 2026 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, compliance, foreign-issuer
TL;DR
**ProQR filed a routine 6-K, no new news, just standard compliance.**
AI Summary
ProQR Therapeutics N.V. filed a 6-K on March 25, 2026, indicating a routine report for foreign issuers. This filing, with accession number 0001104659-26-034158, includes two documents: the 6-K form itself and an Exhibit 99.1. For investors, this specific filing doesn't contain new material financial or operational news, but rather serves as a standard compliance update for a company based in Leiden, Netherlands, which is important for maintaining its listing and transparency with U.S. regulators.
Why It Matters
This filing is a standard compliance update, indicating ProQR Therapeutics N.V. is meeting its regulatory obligations as a foreign issuer, which is crucial for maintaining investor confidence and market access.
Risk Assessment
Risk Level: low — This 6-K filing is a standard regulatory report and does not introduce new financial or operational risks.
Analyst Insight
Investors should recognize this as a standard regulatory update, not an event signaling new financial or operational developments. It's a sign of ongoing compliance, which is generally positive for long-term stability but doesn't warrant immediate trading action.
Key Numbers
- 2 — Number of Documents (The filing includes the 6-K form and Exhibit 99.1.)
- 11192 — Size of FORM 6-K (The size in bytes of the main 6-K document.)
- 13797 — Size of EXHIBIT 99.1 (The size in bytes of the accompanying exhibit.)
Key Players & Entities
- ProQR Therapeutics N.V. (company) — the filer of the 6-K report
- 0001612940 (company) — CIK of ProQR Therapeutics N.V.
- 0001104659-26-034158 (other) — SEC Accession No. for the filing
- 2026-03-25 (date) — Filing Date and Period of Report
Forward-Looking Statements
- ProQR Therapeutics N.V. will continue to file routine compliance documents as required by the SEC. (ProQR Therapeutics N.V.) — high confidence, target: 2027-03-25
FAQ
What is the purpose of a 6-K filing for ProQR Therapeutics N.V.?
A 6-K filing is a 'Report of foreign issuer' under Rules 13a-16 and 15d-16, used by foreign private issuers like ProQR Therapeutics N.V. to furnish the SEC with information that is material to investors and made public in their home country or filed with a foreign stock exchange.
When was this specific 6-K filing submitted and accepted by the SEC?
This 6-K filing was submitted on March 25, 2026, and accepted on the same date at 08:01:55.
How many documents are included in this 6-K submission?
There are two documents included in this submission: 'FORM 6-K tm269800d1_6k.htm' and 'EXHIBIT 99.1 tm269800d1_ex99-1.htm'.
What is the CIK (Central Index Key) for ProQR Therapeutics N.V.?
The CIK for ProQR Therapeutics N.V. is 0001612940.
What is the business address and contact number for ProQR Therapeutics N.V. as listed in the filing?
The business address is ZERNIKEDREEF 9 LEIDEN P7 2333 CK, and the contact number is 31 88 166 7000.
Filing Stats: 273 words · 1 min read · ~1 pages · Grade level 8.9 · Accepted 2026-03-25 08:01:55
Filing Documents
- tm269800d1_6k.htm (6-K) — 11KB
- tm269800d1_ex99-1.htm (EX-99.1) — 13KB
- 0001104659-26-034158.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROQR THERAPEUTICS N.V. Date: March 25, 2026 By: /s/ Dennis Hom Dennis Hom Chief Financial Officer INDEX TO EXHIBITS Number Description 99.1 Press Release of ProQR Therapeutics N.V. dated March 25, 2026.